Novartis AG
NVS Healthcare Drug Manufacturers General
Novartis AG’s revenue for fiscal 2025 (year ended December 2025) was $56.7 billion, up 9.57% from fiscal 2024.
- Revenue
- +4.67%
- EPS
- −69.1%
- Free cash flow
- −17.8%
- Total debt
- +53.9%
Quarter to September 2026, against a year earlier
Follow NVS
Alert me
Novartis AG (NVS) EV/FCF
As of 5 November 2026, Novartis AG (NVS) trades at a EV/FCF of 24.4×. Over the past ten years it has ranged from 12.8× (October 2023) to 24.8× (November 2026); the current reading is higher than 100% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 18.8× | 23.32% |
| FY2024 | 15.2× | (3.90%) |
| FY2023 | 15.8× | (3.34%) |
| FY2022 | 16.4× | 12.40% |
| FY2021 | 14.6× | (27.73%) |
| FY2020 | 20.2× | 17.82% |
| FY2019 | 17.1× | 2.89% |
| FY2018 | 16.6× | (16.49%) |
| FY2017 | 19.9× | 4.34% |
| FY2016 | 19.1× | (12.49%) |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 21.8× | (2.31%) |
| Jun 2026 | 22.3× | 8.93% |
| Mar 2026 | 20.4× | 8.97% |
| Dec 2025 | 18.8× | 20.73% |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| GILD Gilead Sciences, Inc. compare | 16.5× |
| PFE Pfizer Inc. compare | 19.9× |
| NVS Novartis AG | 24.4× |
| MRK Merck & Co., Inc. compare | 25.3× |
| NVO Novo Nordisk A/S compare | 25.4× |
| ABBV AbbVie Inc. compare | 30.8× |
| AMGN Amgen Inc. compare | 31.8× |
| JNJ Johnson & Johnson compare | 32.2× |
| AZN AstraZeneca PLC compare | 49.5× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on NVS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement